Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma
European Respiratory Journal · 2023-03 · 61 (3) · 2201193
DOI: 10.1183/13993003.01193-2022 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, online erschienen am 23.02.2023. Verfasst von Gail M Gauvreau und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McMaster University, Hamilton, ON, Canada gauvreau@mcmaster.ca. Hauptthemen laut MEDLINE: Asthma, Hypersensitivity, Immediate. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AllerGen National Center of Excellence, Novartis Pharma AG, Basel, Switzerland.
Abstract (Originalsprache)
Background
Thymic stromal lymphopoietin (TSLP) is a key upstream regulator driving allergic inflammatory responses. We evaluated the efficacy and safety of ecleralimab, a potent inhaled neutralising antibody fragment against human TSLP, using allergen inhalation challenge (AIC) in subjects with mild atopic asthma.
Methods
This was a 12-week, randomised, double-blind, placebo-controlled, parallel-design, multicentre allergen bronchoprovocation study conducted at 10 centres across Canada and Germany. Subjects aged 18–60 years with stable mild atopic asthma were randomised (1:1) to receive 4 mg once-daily inhaled ecleralimab or placebo. Primary end-points were the allergen-induced change in forced expiratory volume in 1 s (FEV 1 ) during the late asthmatic response (LAR) measured by area under the curve (AUC 3–7h ) and maximum percentage decrease (LAR%) on day 84, and the safety of ecleralimab. Allergen-induced early asthmatic response (EAR), sputum eosinophils and fractional exhaled nitric oxide ( F ENO ) were secondary and exploratory end-points.
Results
28 subjects were randomised to ecleralimab (n=15) or placebo (n=13). On day 84, ecleralimab significantly attenuated LAR AUC 3–7h by 64% (p=0.008), LAR% by 48% (p=0.029), and allergen-induced sputum eosinophils by 64% at 7 h (p=0.011) and by 52% at 24 h (p=0.047) post-challenge. Ecleralimab also numerically reduced EAR AUC 0–2h (p=0.097) and EAR% (p=0.105). F ENO levels were significantly reduced from baseline throughout the study (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, McMaster University, Hamilton, ON, Canada gauvreau@mcmaster.ca.
- These authors contributed equally to this work.
- Fraunhofer Institute for Toxicology and Experimental Medicine and Hannover Medical School, Hannover, Germany.
- Centre for Lung Health, University of British Columbia, Vancouver, BC, Canada.
- Québec Heart and Lung Institute, Laval University, Québec, QC, Canada.
- Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
ORCID-Profile: Jens M Hohlfeld, Maciej Cabanski, Paul M O'Byrne
Förderung
- AllerGen National Center of Excellence
- Novartis Pharma AG, Basel, Switzerland
Zitieren
APA
Gauvreau, G. M., Hohlfeld, J. M., FitzGerald, J. M., Boulet, L. P., Cockcroft, D. W., Davis, B. E., Korn, S., Kornmann, O., Leigh, R., Mayers, I., Watz, H., Grant, S. S., Jain, M., Cabanski, M., Pertel, P. E., Jones, I., Lecot, J. R., Cao, H., & O'Byrne, P. M. (2023). Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. European Respiratory Journal, 61(3), 2201193. https://doi.org/10.1183/13993003.01193-2022
Vancouver
Gauvreau GM, Hohlfeld JM, FitzGerald JM, Boulet LP, Cockcroft DW, Davis BE, et al. Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. European Respiratory Journal. 2023;61(3):2201193. doi:10.1183/13993003.01193-2022
BibTeX
@article{Gauvreau2023,
author = {Gauvreau, Gail M and Hohlfeld, Jens M and FitzGerald, J Mark and Boulet, Louis-Philippe and Cockcroft, Donald W and Davis, Beth E and Korn, Stephanie and Kornmann, Oliver and Leigh, Richard and Mayers, Irvin and Watz, Henrik and Grant, Sarah S and Jain, Monish and Cabanski, Maciej and Pertel, Peter E and Jones, Ieuan and Lecot, Jean R and Cao, Hui and O'Byrne, Paul M},
title = {Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma},
journal = {European Respiratory Journal},
year = {2023},
volume = {61},
number = {3},
pages = {2201193},
doi = {10.1183/13993003.01193-2022}
}
EUVIMED